Mythic Therapeutics
Mythic Therapeutics, based in Waltham, MA, develops advanced antibody-drug conjugates (ADCs) for cancer treatment, focusing on enhancing efficacy and reducing side effects through its FateControl technology.
Services
Mythic Therapeutics specializes in developing antibody-drug conjugates (ADCs) focused on cancer treatment. The company's innovative approach utilizes FateControl technology to improve the uptake of ADCs in cancer cells, thereby enhancing the efficacy of treatments while minimizing adverse effects on healthy cells. This service aims to provide more effective and safer therapeutic options for cancer patients.
Innovative FateControl Technology
Mythic Therapeutics leverages its proprietary FateControl technology to increase ADC uptake in cancer cells. This technology is designed to optimize the delivery of chemotherapy drugs directly to tumors, reducing the impact on normal cells and thereby minimizing side effects. FateControl aims to significantly improve treatment outcomes by boosting efficacy and expanding the therapeutic window.
Clinical Trial KisMET-01
Mythic Therapeutics is currently conducting a Phase 1 clinical trial named KisMET-01. This trial focuses on evaluating MYTX-011, a targeted therapy for non-small cell lung cancer (NSCLC) patients with cMET overexpression. MYTX-011 is engineered to enhance the delivery of chemotherapy to tumor cells while reducing toxicity. The KisMET-01 trial is a critical step in assessing the safety and efficacy of this promising treatment.
Location
Mythic Therapeutics is located in Waltham, Massachusetts, USA. This strategic location provides access to a vibrant biotech community and numerous research institutions, facilitating collaboration and innovation in the development of advanced cancer therapies.